Item 5. Market for Registrant’s Common Equity
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Our common stock is traded on the Nasdaq Global Select Market under the symbol “NBIX”.
As of February 5, 2025, there were 39 stockholders of record of our common stock. We have not paid any cash dividends on our common stock since inception and do not anticipate paying cash dividends in the foreseeable future.
Recent Sales of Unregistered Securities
There were no unregistered sales of our equity securities during 2024.
Issuer Purchases of Equity Securities
In October 2024, our Board of Directors authorized a share repurchase program to repurchase up to $300.0 million of the Company’s common stock. Through the end of the fourth quarter of 2024, we have repurchased shares of the Company’s common stock having a value of $240.5 million under this program. The number of shares and average price paid per share for shares repurchased in each month of the fourth quarter of 2024 are set forth in the table below:
Period Total Number of Shares
Repurchased Average Price
Paid
Per Share Total Number of
Shares Purchased as
Part of Publicly
Announced Program (1)
Dollar Value of
Shares that May Yet
Be Purchased
Under the Program (1)
October 2024 — $ — — $ 300,000,000
November 2024 (1)
1,995,510 $ 120.53 1,995,510 $ 59,481,180
December 2024 — $ — — $ 59,481,180
1,995,510 $ 120.53 1,995,510
_________________________
(1) In November 2024, we paid $300.0 million under an accelerated share repurchase (ASR) transaction and received an initial delivery of 2.0 million shares. The ASR transaction terminated in February 2025, at which time we became contractually entitled to receive an additional 0.3 million shares upon settlement. Refer to Note 6 to the consolidated financial statements.
50
STOCK PERFORMANCE GRAPH AND CUMULATIVE TOTAL RETURN*
The following graph presents the cumulative total stockholder return assuming the investment of $100 on December 31, 2019 (and the reinvestment of dividends thereafter) in each of (i) Neurocrine Biosciences, Inc.’s common stock, (ii) the Nasdaq Composite Index and (iii) the Nasdaq Biotechnology Index. The comparisons in the graph below are based upon historical data and are not indicative of, or intended to forecast, future performance of our common stock or Indexes.
* The material in this section is not “soliciting material”, is not deemed “filed” with the Securities and Exchange Commission and is not to be incorporated by reference into any of our SEC filings whether made before or after the date hereof and irrespective of any general incorporation language in any such SEC filing except to the extent we specifically incorporate this section by reference.
51
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the is authoritative for anything you rely on.